Skip to main content
SpringerLink
Log in

Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma

  • Case Report
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

A patient with advanced and chemotherapy-refractory nodal marginal zone B-cell lymphoma was given a course of chimeric CD 20 monoclonal antibody Rituximab. Partial response was observed without any major toxicities. Retreatment with Rituximab for disease progression six months after the first course led to partial remission. Adjuvant radiotherapy was given for the residual disease and, currently, patient's disease remains stable eight months after the second course of Rituximab. This case demonstrates the therapeutic efficacy and feasibility of retreatment with Rituximab for relapsed or refractory low grade lymphoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McLaughlin Pet al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.J Clin Oncol 1998;8: 2825–2833.

    Article  Google Scholar 

  2. Davis TAet al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of Rituximab.J Clin Oncol 1999;6: 1851–1857.

    Article  Google Scholar 

  3. Bagley CM Jr, Devita VT Jr, Berard CW, Canellos GP. Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincritine and prednisolone.Ann Intern Med 1972;76: 219–225.

    Article  PubMed  Google Scholar 

  4. Wilson WHet al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.J Clin Oncol 1993;8: 1573–1582.

    Article  Google Scholar 

  5. Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ. IMVP-16: an effective regimen for patients with lymphoma who relapsed after initial combination chemotherapy.Blood 1982;60: 693–697.

    Article  CAS  PubMed  Google Scholar 

  6. Velasquez WSet al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).Blood 1988;71 117–122.

    Article  CAS  PubMed  Google Scholar 

  7. International Lymphoma Study Group. The Non-Hodgkin's Lymphoma Project: A clinical evaluation of the International Lymphoma Study Group classification of the non-Hodgkin's lymphoma.Blood 1997;89: 3909–3818.

    Article  Google Scholar 

  8. Nathwani BN, Drachenberg MR, Hernandez AM, Levine AM, Sheibani K. Nodal Monocytoid B-Cell Lymphoma (Nodal Marginal Zone B-Cell Lymphoma).Seminars in Haematology 1999;36: 128–138.

    CAS  Google Scholar 

  9. Jensen M, Winkler U, Manzke O, Diehl V, Engert A. Rapid tumour lysis in a patients with B-cell chronic lymphocytic leukemia and lymphocytosis treated with anit-CD20 monoclonal antibody (IDEC-C2B8, rituximab).Ann Hematol 1998;77: 89–91.

    Article  CAS  PubMed  Google Scholar 

  10. Lim L-C, Koh L-P, Tan P. Fatal cytokine release syndrome with chimeric Anti-CD 20 monoclonal antibody Rituximab in a 71-year-old patient with chronic lymphocytic leukemia.J Clin Oncol 1999;17: 1962–1963.

    CAS  PubMed  Google Scholar 

  11. Winkler Uet al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD 20 monoclonal antibody (Rituximab, IDEC-C2B8).Blood 1999;94: 2217–2224.

    Article  CAS  PubMed  Google Scholar 

  12. Davis Tet al. Retreatment with Rituximab have significant efficacy, do not cause HAMA, and are a viable minimally toxic alternative in relapsed or refractory non-Hodgkin's lymphoma (NHL). Presented at the 39th Annual Meeting of the American Society of Hematology December 5–9, 1997; San Diego, California.

  13. Cruczman MSet al. Treatment of patients with low-grade B-cell lymphoma with the combination of anti-CD 20 monoclonal antibody and CHOP chemotherapy.J Clin Oncol 1999;17: 268–276.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diagnostic Radiology, Singapore General Hospital, Singapore

    C-H Thng

  2. Department of Haematology, Singapore General Hospital, Outram Road, 169608, Singapore

    L-P Koh & L-C Lim

Authors
  1. L-P Koh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L-C Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C-H Thng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L-P Koh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koh, LP., Lim, LC. & Thng, CH. Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma. Med Oncol 17, 225–228 (2000). https://doi.org/10.1007/BF02780533

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02780533

Keywords

Search

Navigation